%0 Journal Article %A Saira Khanna %A Rahul Komati %A David A Eichenbaum %A Ishani Hariprasad %A Thomas A Ciulla %A Seenu M Hariprasad %T Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review %D 2019 %R 10.1136/bmjophth-2019-000398 %J BMJ Open Ophthalmology %P e000398 %V 4 %N 1 %X Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents. %U https://bmjophth.bmj.com/content/bmjophth/4/1/e000398.full.pdf